Is ChondroFiller injection an option for my thumb?

Thumb base pain — the ache that flares when turning a key, opening a jar, or pinching a pen — is one of the more disabling presentations of joint wear in the hand. If you've been told you have rhizarthrosis, thumb CMC arthritis, or basal joint arthritis, these terms all describe the same thing: progressive wear of the trapeziometacarpal (TMC) joint where the thumb meets the wrist.

ChondroFiller injection is an ultrasound-guided outpatient treatment that can be delivered directly into the TMC joint as an injectable collagen scaffold — no surgery, no general anaesthetic, no theatre time. It is a CE-marked Class III medical device, and in the UK it is available at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads delivery of the procedure. It is not available on the NHS or through private medical insurance.

This article sets out who is likely to be a candidate, what the published clinical evidence shows, and how treatment intensity is typically matched to the stage of cartilage wear.

Why the thumb base is difficult to treat without surgery

The trapeziometacarpal joint is small, sits deep within the thenar eminence, and bears substantial compressive force during everyday grip and pinch activities. That combination of tight anatomy and high mechanical load makes it one of the more technically demanding joints for any surgical intervention.

Conventional surgical options — trapeziectomy (removal of the trapezium bone) and ligament reconstruction with tendon interposition — have long been the standard response to advanced rhizarthrosis. Both approaches involve restructuring or removing tissue, weeks in a cast, and several months of hand therapy before function returns. Arthroscopic access to the TMC joint is technically feasible but requires specialist skill; the confined space and proximity to neurovascular structures raise the procedural stakes relative to larger, more accessible joints.

An injectable scaffold approach sidesteps these constraints in a specific way. Because ChondroFiller injection is administered into a fluid joint environment under image guidance, it does not require debridement, joint drying, or open access. The scaffold is delivered directly into the joint space through a fine needle — positioned under fluoroscopic or ultrasound guidance — allowing precise placement into a constrained site that would otherwise demand theatre access to reach safely. The current service pathway uses image-guided outpatient injection, and it is that guidance capability which makes the injectable route anatomically viable at the thumb base. Where surgical risk is disproportionate to the degree of cartilage wear, the non-operative route carries clear practical weight.

How ChondroFiller injection works at the thumb base

Injected as a liquid, ChondroFiller converts to a gel on contact with the synovial fluid already present in the joint. That phase-change is central to how it works: the gel settles over degenerated bone surfaces as a protective, load-absorbing coating, occupying the space where cartilage has thinned without requiring the removal of any remaining tissue as a precondition for delivery.

Once in place, the scaffold acts through a process called acellular matrix-induced chondrogenesis. The collagen matrix — Type I collagen, derived from a murine source and classified as acellular, meaning it contains no living donor cells — provides a chemotactic scaffold that draws the patient's own progenitor cells inward from the surrounding synovium and subchondral bone. Over subsequent weeks, those recruited cells support the body's own repair processes within the defect. The treatment is not described as regrowing cartilage; it supports the biological conditions in which endogenous repair can occur.

As a Class III CE-marked medical device, ChondroFiller is subject to the most stringent regulatory tier for implantable and long-term-contact medical devices in Europe — a higher standard than applies to viscosupplements or simple joint injections.

At the London Cartilage Clinic on Harley Street, the injection is delivered as an image-guided outpatient appointment. A fine needle is positioned precisely into the TMC joint under ultrasound guidance, and the scaffold is introduced directly into the fluid-filled joint space. The additive nature of the delivery — laying a fresh collagen matrix over the joint surface rather than excising damaged tissue — is what makes this approach practicable within the confined anatomy of the thumb base without the access demands that surgical routes require.

What the clinical evidence shows for rhizarthrosis

The most direct clinical evidence comes from a 2023 prospective study by Corain and colleagues, which enrolled 43 patients with trapeziometacarpal osteoarthritis and delivered a single intra-articular ChondroFiller injection into the TMC joint, stratified by Eaton-Littler staging. Group A covered Stage I–II (earlier wear) and Group B covered Stage III–IV (advanced wear); both were followed at 30 days and 6 months.

Across both groups, all measured endpoints reached statistical significance. NRS pain scores fell meaningfully at each time point. DASH questionnaire scores — capturing disability across arm, shoulder, and hand function — improved in parallel. Grip and pinch strength, tested objectively with the Jamar dynamometer and a standardised pinch test, increased in both groups: directly relevant gains, given that gripping and pinching are the functional demands most disrupted by rhizarthrosis.

Post-treatment MRI corroborated what patients reported. Scans confirmed a reduction in bone marrow oedema, a decrease in periarticular effusion, and visible widening of the joint space — structural changes that aligned with the symptomatic and functional improvements recorded at the same time points. That convergence of patient-reported outcomes, objective functional tests, and imaging findings — sustained across both early and advanced disease subgroups — makes this the strongest direct evidence currently available for ChondroFiller injection at the thumb base.

The evidence does, however, have clear limits, and they are worth acknowledging without alarm. All thumb-specific data derives from this single prospective cohort; no randomised controlled trial exists, and follow-up does not extend beyond six months. The UK evidence base for ChondroFiller in rhizarthrosis is still developing. Broader clinical experience — more than 19,000 ChondroFiller cases performed globally, with published outcomes including a 30-point IKDC gain in the knee and a 33-point Harris Hip Score gain in the hip — supports biological plausibility and a consistent safety profile across joints, but those large-joint benchmarks should not be read across as thumb-joint guarantees.

Who is a candidate and how treatment intensity varies by stage

Eaton-Littler staging — already central to the Corain study design — is also the practical framework for deciding which protocol, if any, is appropriate at assessment.

Earlier-to-moderate wear (broadly Stage I–II). When meaningful joint space remains and cartilage degradation has not yet reshaped the joint architecture, a single ChondroFiller injection is the typical starting point. The scaffold needs existing tissue to work with and room within the joint to gel and settle; Stage I–II presents the biological conditions most conducive to matrix-induced chondrogenesis. Guide costs at the London Cartilage Clinic start from approximately £3,000 per injection.

Advanced wear (Stage III–IV). Significant cartilage loss alters both the bone-end surfaces and the synovial environment simultaneously. A single scaffold addresses only one of those compartments, which is why the dual-injection protocol pairs ChondroFiller (2.3 mL, applied to the bone-end cartilage surfaces) with Arthrosamid (6 mL, a polyacrylamide hydrogel that integrates into the synovial lining). These are not interchangeable products doing the same job: ChondroFiller is the regenerative scaffold component; Arthrosamid is a non-regenerative hydrogel targeting the synovium rather than the cartilage surface. Addressing both compartments is the clinical rationale for the combination, not simply escalating dose. Guide costs for this protocol start from approximately £6,000.

Extreme presentations. Autologous mesenchymal stem cells may be added as a further biological layer alongside both injections — a tri-active approach reserved for the most advanced cases, with guide costs from approximately £11,000. All figures are subject to confirmation at a clinical assessment.

Who falls outside this pathway. Where joint destruction has progressed to complete structural collapse with severe deformity, injection-based treatment is unlikely to offer meaningful benefit and surgical assessment becomes the more appropriate conversation.

Individual suitability, expected response, and protocol selection are determined at the London Cartilage Clinic on Harley Street through clinical examination, imaging review, and Eaton-Littler staging — no tier carries a guarantee of a specific outcome.

Getting assessed at London Cartilage Clinic

Whether ChondroFiller injection belongs in the thumb-base pathway depends on what staging reveals — which is precisely why the assessment matters as much as the treatment itself. Imaging review and Eaton-Littler classification, carried out before any protocol is agreed, determine whether a single injection, a dual approach, or a surgical referral is the more honest conversation to have.

In the UK, ChondroFiller injection for rhizarthrosis is delivered at the London Cartilage Clinic on Harley Street — the UK-certified centre for the product. Professor Paul Y. F. Lee leads delivery there; image-guided scaffold placement is technique-sensitive, and precision in that step materially influences what the scaffold can do inside a joint as constrained as the thumb base.

Assessments can be arranged via londoncartilage.com.

1. [1] Osteoarthritis at the base of the thumb. https://en.wikipedia.org/?curid=40934678 https://en.wikipedia.org/?curid=40934678